GW Pharmaceuticals PLC- (NASDAQ:GWPH) Short Interest Update

GW Pharmaceuticals PLC- (NASDAQ:GWPH) saw a significant increase in short interest in January. As of January 31st, there was short interest totalling 6,230,000 shares, an increase of 8.9% from the January 15th total of 5,720,000 shares. Based on an average trading volume of 740,100 shares, the days-to-cover ratio is currently 8.4 days. Approximately 20.3% of the shares of the company are short sold.

A number of equities research analysts have weighed in on GWPH shares. HC Wainwright reissued a “buy” rating and set a $170.00 target price on shares of GW Pharmaceuticals PLC- in a report on Wednesday, December 18th. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a report on Tuesday, January 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $174.00 target price on shares of GW Pharmaceuticals PLC- in a report on Wednesday, November 6th. Evercore ISI started coverage on shares of GW Pharmaceuticals PLC- in a report on Friday, February 7th. They set a “buy” rating and a $260.00 target price on the stock. Finally, Oppenheimer reduced their target price on shares of GW Pharmaceuticals PLC- to $222.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $197.50.

In other GW Pharmaceuticals PLC- news, CEO Justin D. Gover sold 5,340 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $9.17, for a total transaction of $48,967.80. Following the sale, the chief executive officer now directly owns 568,865 shares of the company’s stock, valued at approximately $5,216,492.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Geoffrey W. Dr Guy sold 900,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $9.44, for a total transaction of $8,496,000.00. Following the sale, the chairman now directly owns 7,421,521 shares in the company, valued at $70,059,158.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 908,916 shares of company stock valued at $8,575,650. 3.60% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of GWPH. Signaturefd LLC raised its position in shares of GW Pharmaceuticals PLC- by 192.5% in the 3rd quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 154 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in GW Pharmaceuticals PLC- by 322.6% during the third quarter. Valeo Financial Advisors LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 200 shares in the last quarter. Trustcore Financial Services LLC boosted its position in GW Pharmaceuticals PLC- by 54.6% during the fourth quarter. Trustcore Financial Services LLC now owns 283 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 100 shares in the last quarter. Squar Milner Financial Services LLC boosted its position in GW Pharmaceuticals PLC- by 300.0% during the third quarter. Squar Milner Financial Services LLC now owns 300 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 225 shares in the last quarter. Finally, PSI Advisors LLC bought a new stake in GW Pharmaceuticals PLC- during the fourth quarter valued at about $41,000. 84.10% of the stock is currently owned by institutional investors.

Shares of NASDAQ:GWPH traded up $0.50 during trading on Friday, reaching $126.64. The stock had a trading volume of 6,667 shares, compared to its average volume of 582,269. The firm’s fifty day moving average is $113.35 and its 200 day moving average is $123.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.60 and a current ratio of 7.33. GW Pharmaceuticals PLC- has a 52 week low of $95.71 and a 52 week high of $196.00. The stock has a market cap of $4.00 billion, a price-to-earnings ratio of -64.23 and a beta of 2.19.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: What are no-load funds?

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.